Display Settings:

Format

Send to:

Choose Destination
Biomarkers. 2012 Jun;17(4):372-8. doi: 10.3109/1354750X.2012.680609. Epub 2012 Apr 19.

Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma.

Author information

  • 1Department of Cell Biology, Hebei University College of Life Sciences, Baoding, China.

Abstract

OBJECTIVES:

To evaluate the diagnostic values of autoantibodies against lymphocyte antigen 6 complex locus K (LY6K) in esophageal squamous cell carcinoma (ESCC).

METHODS:

After cloning, expressing, and purifying LY6K as fusion proteins, LY6K autoantibodies were measured in 62 patient and 58 control serum samples using enzyme-linked immunosorbent assay (ELISA). Reverse transcription polymerase chain reaction (RT-PCR) was used to measure the LY6K mRNA levels in ESCC and adjacent tissues.

RESULTS:

LY6K autoantibodies were found significantly higher in patients than controls. The area under the receiver-operating characteristic (ROC) curve (AUC) was 0.85, and the optimal sensitivity and specificity for ESCC detection were 80.6 and 78.7%, respectively. LY6K mRNA expressions in patients were upregulated.

CONCLUSIONS:

Autoantibodies against LY6K may be a good diagnostic biomarker for ESCC.

PMID:
22515502
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk